Previous 10 | Next 10 |
home / stock / lly / lly articles
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and...
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (ARCA:IYH), ...
Goldman Sachs analysts re-rated Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), citing the potential for their weight-loss drugs. The ...
Wednesday, the FDA granted accelerated approval to Eli Lilly And Co’s (NYSE:LLY) selpercatinib (Retevmo) for pediatric patients two years of ...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Apple Inc. (NASDAQ:AAPL) is a “buy here.” Apple's iPhone s...
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous...
David Ricks, CEO of Eli Lilly and Co (NYSE:LLY), expressed confidence in meeting the lofty revenue expectations set by Bank of America for the comp...
A team of Chinese scientists has successfully cured a patient’s diabetes using cell therapy, marking a global first. What Happened: The patie...
Tesla and SpaceX CEO Elon Musk made a bold prediction about the future cost of Novo Nordisk’s (NYSE:NVO) Ozempic, a popular drug being used ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...